Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 100

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 100
---
 normotensive patients, with encouraging
efficacy reflected in a high disease control rate and prolonged progression-free survival. The authors further recommended continued
investigation of this approach in larger trials.

Additionally, a retrospective study by Wilop et al. (3) examined the impact of ARBs and other agents on survival in patients with advanced non-small-cell lung cancer undergoing
first-line platinum-based chemotherapy. The researchers found that the addition of an ARB to platinum-based therapy was associated with
prolonged survival. This clinical observation aligns with previous experimental findings suggesting that ARBs may exert direct antiproliferative
effects on tumor cells and/or their microenvironment.

Fig. 12. Estimated survival from 1st cycle
of chemotherapy in the entire patient group according to long-term medication with (n = 52) or without (n =235) ACEI (Angiotensin converting
enzyme inhibitor) or ARB (P =0.03, log rank test) (3)

Described above clinical and preclinical findings
suggest that blockade of the angiotensin receptor may favorably modulate the tumor microenvironment, reduce immunosuppressive signaling,
and enhance responsiveness to anticancer agents. Based on this, we believe that administration of our novel formulation of Nano-Candesartan
could provide dual benefits: maintaining stable blood pressure profiles in patients while offering a clinically significant and tolerable
therapeutic effect in oncology settings.

Pre-clinical Studies on Nano-Candesartan

Preclinical exploratory studies performed
in Prof. Barenholz’s laboratory evaluated liposomal formulations of angiotensin receptor blockers (ARBs), including Candesartan,
in animal models of several solid tumors. These studies investigated tolerability and biological activity of liposomal ARBs in combination
with standard anticancer agents. While exploratory in nature and not designed to demonstrate definitive clinical efficacy, the results
lend scientific rationale for further investigation of Nano-Candesartan as a combination therapy candidate. No preclinical results were
obtained from third-party studies; all studies were conducted exclusively by Prof. Barenholz’s team.

<div align='center'>64</div>

Key findings of pre-clinical results obtained
by Prof. Chezy Barenholz and his team at the Hebrew University of Jerusalem:

| - | Passive targeting. PEGylated                                                             
 nano-liposomes can exploit the enhanced permeability and retention (EPR) effect allowing 
 for passive targeting